Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen In Insulin Therapy

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Novo Nordisk today announced results of a new study that further demonstrated the safety and efficacy of insulin Levemir(R) (insulin detemir [rDNA origin] injection). Patients with type 2 diabetes were able to adjust their own dosage of Levemir(R) and achieve improvements in blood sugar, comparable to dosing adjusted by their primary care physician. This improvement in A1c levels was observed with minimal weight change and without increases in rates of hypoglycemia.(1) The data were presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.

"The study is a testament to the safety of Levemir(R), as patients were able to adjust their basal insulin dose on their own and achieve the same level of glycemic control as when guided by their doctor, while reducing the risk of hypoglycemia," said Luigi Meneghini, MD, MBA, Associate Professor of Clinical Medicine and the Director of the Eleanor and Joseph Kosow Diabetes Treatment Center at the Diabetes Research Institute, Miami, FL. "Since having type 2 diabetes requires a great deal of self-management, these findings will help empower patients to work more closely as partners with their physician to take control of their insulin treatment. The potential of improved self- management is made possible by insulin analogs like Levemir(R), which provide effective basal insulin coverage, and, as shown in this study, the added benefit of minimal weight change."

The new data were obtained from the insulin detemir 303 Algorithm tested in a Randomized Clinical Trial: The US PREDICTIVE(TM) 303 Trial (Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation), which included 5,604 patients. The data showed that patient sel
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/24/2009)...24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgianman...cident,wasactuallyfullyconsciousandawakeduringthat...heDynaVoxEyeMaxwasfeaturedinthesegmenttoillustrate...nunlockcommunication. ,, WHEN:GoodMorningAmeric...navoxtech.com ,, WHO:RomHoubenswasanenginee...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--QuestDiagnosticsIncorp...nostictesting,informationandservices,announcedthat...lthcareConferenceinNewYorkCity.Thepresentationissc...nTime. ,, Duringtheconference,thecompanywillrea...%,operatingincometoexceed18%ofrevenues,anddilutede...
(Date:11/24/2009).../PRNewswire-FirstCall/--AnadysPharmaceuticals,Inc....e21stAnnualPiperJaffrayHealthcareConferenceonTuesd...ferenceisbeingheldatTheNewYorkPalaceHotel.SteveWor...ys,willprovideanoverviewofAnadysanditsclinicaldeve...epresentationwillbesimultaneouslywebcastandcanbeac...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Video 3A HHS Launches Best Bones Forever 21 55789 1Video 3A HHS Launches Best Bones Forever 21 55789 2Stemedica Achieves Major Milestone Company Receives License to Manufacture Clinical Grade Stem Cells 4924 1Stemedica Achieves Major Milestone Company Receives License to Manufacture Clinical Grade Stem Cells 4924 2Workplace bullying is associated with sleep disturbances 55786 1Workplace bullying is associated with sleep disturbances 55786 2Workplace bullying is associated with sleep disturbances 55786 3
...l 25, 2007-Labtec GmbH (Langenfeld,Germany), a sp...esults from a multiple dose clinical study for the...quo;Today, we are pleased to announce the successf... Sufentanil,TDS®. Our goal for this program wa...,” says Dr. Armin Breitenbach, Labtec,s,Dire...
...S WIRE)--Apr 26, 2007 - Columbia,Laboratories, Inc...results from the ongoing data analysis of the rece...ble-blind Phase III clinical,trial of PROCHIEVE(R)...rm birth in women with a previous preterm birth ea...ble effect of PROCHIEVE 8%,in delaying cervical sh...
Other Medicine Technology:Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3
(Date:11/25/2009)... may lead to new drugs for people, researchers say... -- Sphingadienes, natural lipid molecules found i... for colon cancer, California researchers have fou...udy authors pointed out that they could help expla...on cancer. , In the study, Dr. Julie Saba, seni...
(Date:11/25/2009)...U College teaches students to use natural treatmen... Burnaby, BC (Vocus) November 25, 2...re the standard, effective treatments in the fight...e medicine to help them cope with the side effects...er of cancer patients using acupuncture and herbal...
(Date:11/25/2009)...nancialFlexibility,AllowingCompanytoAccessCapitala...ire-FirstCall/-LabopharmInc.(TSX:DDS;NASDAQ: DDSS ...ibutionagreement(SEDA)withYAGlobalMasterSPVLtd.,af...heagreement,YAhascommittedtoprovideupto$25milliono...etion,throughthepurchaseofnewlyissuedLabopharmcomm...
(Date:11/25/2009)...edicinal herb proves effective in animal study , ...An herb called Brazilian mint treats pain as effec...s report. , Traditional healers in Brazil have ...ge of health problems, including headaches, stomac...scientifically prove the pain-relieving properties...
(Date:11/25/2009)...Newswire/-- , -LatestSurveyFromTheITJobBoardR...ImpactonourHealth , 81percentofITprosbelievet...y[1]conductedbyTheITJobBoard, http://www.theitjob...nt),believetheimpactisanegativeone. , Moretha...ve,increasedoverthelastyear-sincetherecessionbegan...
Breaking Medicine News(10 mins):Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holistic and Western Medicine Combined Can Fight Cancer 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:It's Official, Work is Bad for Our Health! 2
...ne tonsillectomy, a surgery that is performed to r... better a year later.// About half of the child...activity Disorder before tonsil surgery no longer ...onsils out were much more likely than a comparison...
...rma suffered from cardiac triple vessel disease, s... recovery of several hours associated with a // co...n minutes and back home in two hours. "More peo...corts Heart Institute and Research Centre here and...
...ernment document, it is stated that Britain needs ... encountered with the pandemic flu sometime in// t...hird of a million people will die if bird flu stri...rely on the antiviral vaccine or drugs to protect ...
...aking all precautionary measures against bird-flu,...bird-flu crisis on the economic health. After boun...rd-flu crisis is the last thing needed so authori... slated to be commissioned in 2009. This will obli...
...e company has announced that it would be providing...to handle specially equipped to handle massively o...0pounds or more. //This is being done at the reque...handled 75 calls where they needed extra manpower ...
...searcher, nearly half of the British population ar... them to an increased risk of osteoporosis or some... University of Leuven in Belgium told the European...le across Europe and more than 30 million in Brita...
Other Medicine News:Health News:Kids Overcome Behavioral And Sleep Problems After Tonsillectomy 2Health News:Kids Overcome Behavioral And Sleep Problems After Tonsillectomy 3Health News:Kids Overcome Behavioral And Sleep Problems After Tonsillectomy 4
Right Angle Dissector
Maryland Dissector
...ion holes and additional electrode tip insulation,...dissection with decreased risk of collateral sprea... options allow the choice between retractable and .... Optimize specific surgical demands safely and ea...
...ion holes and additional electrode tip insulation,...dissection with decreased risk of collateral sprea... options allow the choice between retractable and .... Optimize specific surgical demands safely and ea...
Medicine Products: